

[Go to old article view](#)

Go To

Acta Ophthalmologica [Explore this journal >](#)[View issue TOC](#)

Volume 91, Issue s252

August 2013

Page 0

Special Issue:

Abstracts from the 2013 European Association for Vision and Eye Research Conference

3723

STARflo™ Glaucoma Implant: 12 month clinical results[S POURJAVAN](#), [N COLLIGNON](#), [V DE GROOT](#)**First published:**6 August 2013 [Full publication history](#)**DOI:**10.1111/j.1755-3768.2013.3723.x [View/save citation](#)**Cited by:**0 articles [Citation tools](#)

Abstract

Purpose STARflo™ Glaucoma Implant is made entirely with silicone STAR® Biomaterial, a flexible tissue-friendly, micro-porous structure designed to reduce fibrotic response and maximize long-term performance. Here we share our 12months experience with the first patients implanted with the STARflo.

Methods Four patients with advanced open angle glaucoma underwent implantation. Under anesthesia, a conjunctival flap and a superficial scleral flap were created. An incision in the second layer of sclera until choroid was performed to insert the implant body in the suprachoroidal space while the STARflo head was inserted into the anterior chamber. The scleral flap was sutured tight.

Results Patient ages were 65.3 years. Mean pre-operative IOP was 37.0 mmHg and mean pre-operative glaucoma medication was 3.25 intake/day. At 12 months (3 cases), mean IOP was 14.3 mmHg and mean glaucoma medication was 1.5 intake/day. No adverse

events were reported during or immediately after the surgical procedure and no device-related adverse events were reported during follow-up. Early post-operative complications included transient hypotony, transient choroidal hemorrhage and transient abnormal macula. Bleb disappeared between month 1 and month 3. One patient, with posttraumatic COAG, was dropped out following a cyclophotocoagulation.

Conclusion clinical results for STARflo have met the safety and performance endpoints of the study and shown encouraging results in the control of the IOP with a reduction of glaucoma medications. Although long-term success still has to be demonstrated, this newly-CE marked device is promising as a novel, suprachoroidal implant for bleb-free, IOP reduction for patient suffering from refractory open angle glaucoma.

Commercial interest

Related content

WILEY

[Browse Publications](#)

[Browse by Subject](#)

[Resources](#)

[Help & Support](#)

[Cookies & Privacy](#)

[Terms & Conditions](#)

[About Us](#)

[Wiley Job Network](#)

[Advertisers & Agents](#)